Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2024 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
March 07, 2024 17:32 ET | Source: The Rosen Law Firm PA

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amplitude, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPL

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Amplitude, Inc. (NASDAQ: AMPL) between September 21, 2021 and...
March 07, 2024 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Launch of CEO Corner Platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future...
March 06, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
February 27, 2024 19:49 ET | Source: The Rosen Law Firm PA

BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
February 21, 2024 08:00 ET | Source: BIOXYTRAN, INC.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
February 09, 2024 19:45 ET | Source: The Rosen Law Firm PA

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIVI

NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and...
February 08, 2024 08:50 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
February 05, 2024 16:02 ET | Source: Invivyd

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
January 31, 2024 05:00 ET | Source: AKAMPION

MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen

Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...